… efficacy and safety of molnupiravir in patients with COVID-19. … Molnupiravir is first oral
antiviral drug to demonstrate a significant benefit in reducing hospitalization or death in mild COVID…

… Molnupiravir has been shown to be effective in preventing … with mild-to-moderate COVID-19.
In this study, we evaluate the efficacy and safety of molnupiravir in Indian patients with mild …

… Authorization in three countries for the treatment of mild COVID-19. The aim of this systematic
review was to find out the safety and efficacy of Molnupiravir in SARS-COV-2 infections. …

… assess the efficacy and safety of molnupiravir in patients with mild or moderate COVID-19. …
thus far of the efficacy and safety of molnupiravir in treating patients with mild to moderate …

… of COVID-19. This study evaluates the efficacy and safety of molnupiravir in addition to …
standard-of-care (SOC) for the treatment of non-hospitalized patients with mild COVID-19. …

… Molnupiravir efficacy and safety were assessed in the MOVe-OUT, a phase 2/3
randomized, double-blind, placebo-controlled trial. This trial enrolled patients with a SARS-CoV-2 …

… efficacy of molnupiravir among mild or moderate COVID-19 … for relevant records were “Molnupiravir,”
“COVID-19,” and “… the effectiveness of molnupiravir with a placebo for COVID-19 …

… Seven out of eight studies on outpatients included patients with mild COVID-19 defined
according to the study protocols (WHO scale 2–3). Another small Phase 3 single-centre study …

… with mild or moderate COVID-19. Patients were randomized to orally receive molnupiravir
(… (primary endpoint) was significantly decreased in the molnupiravir group (median, 9 days) …

… It is mentioned in the plan that the applicable population of molnupiravir is adult patients
with mild and moderate disease within 5 days of onset and high risk factors for progression to …